BRAF and melanoma: Although PD-1 blockade was effective regardless of the patient’s BRAF mutation status in some trials (12, 13), existing data demonstrated an ORR of 15% in Chinese BRAF V600-mutant melanoma patients treated with pembrolizumab (14).